Recent Updates
Recently added Catalysts
BMRN Positive Sentiment Score: 70/100

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will...

Key Takeaway: BioMarin Pharmaceutical Inc. has announced that its CFO, Brian Mueller, will present at the 22nd Annual Morgan Stanley Global Healthcare Conference on September 5, 2024. The presentation will be available via a live audio webcast, with an archived version accessible later. BioMarin, known for its focus on genetic therapies, continues to lead in developing treatments for rare genetic disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Brian Mueller will present at a prestigious healthcare conference.
  • BioMarin has a strong history of transforming lives through genetic discovery.
  • The company boasts eight commercial therapies for rare genetic disorders.

Full Press Release Details

SAN RAFAEL, Calif. , Aug. 29, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Brian Mueller , Executive Vice President, Chief Financial Officer of BioMarin will present at the 22 nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024 , at 7:45 AM PT / 10:45 AM ET in New York, NY .
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/ . An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com .
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 650) 374-2803
SOURCE BioMarin Pharmaceutical Inc.

21 %

Frequently Asked Questions

When will BioMarin present at the Morgan Stanley Healthcare Conference?

BioMarin will present on September 5, 2024, at 7:45 AM PT.

Where can I access the live webcast of BioMarin's presentation?

The live webcast is available at https://investors.biomarin.com/.

What is BioMarin's focus as a biotechnology company?

BioMarin focuses on transforming lives through genetic discovery and targeted therapies.

How many commercial therapies has BioMarin developed?

BioMarin has developed eight transformational commercial therapies.

Last updated: Aug 29, 2024